No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.
www.thyrocare.comNo one on the platform currently holds THYROCARE.NS.
No tracked institution reports a position in THYROCARE.NS as of their last filing.
No one on the platform has traded THYROCARE.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 26.5% | 19.0% | 19.7% | — | — | — |
| Rev. Growth % | 20.6% | 10.9% | ||||
| Profit Margin % | 19.7% | 17.5% | 20.1% | |||
| Free Cash Flow Margin % | 23.6% | 18.5% | 19.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $9.9B | +21.4% | $13.27 | $12.30–$13.69 | — | 5 |
| 2028 | $11.6B | +17.0% | $16.04 | $15.15–$16.44 | — | 5 |
| 2029 | $14.1B | +21.0% | $19.65 | $19.24–$20.34 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $6.63 | $3.30 | -50.2% |
| 2026-05-07 | $5.40 | $3.18 | -41.1% |
| 2026-01-28 | $4.50 | $4.30 | -4.4% |
| 2025-07-23 | $1.70 | $2.43 | +42.9% |
| 2025-04-23 | $1.60 | $2.10 | +31.3% |
| 2025-01-23 | $1.40 | $1.20 | -14.3% |
| 2024-10-23 | $1.70 | $1.70 | +0.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| THYROCARE.NSThyrocare Technologies Limited | $544.45 | -0.96% | $86.7B | — |
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited |
| $349.65 |
| +2.40% |
| $56.9B |
| — |
| KOVAI.BOKovai Medical Center and Hospital Limited | $6014.60 | -3.29% | $65.8B | — |
| METROPOLIS.BOMetropolis Healthcare Limited | $572.30 | -2.25% | $119.1B | — |
Source: Financial Modeling Prep · peers by sector/industry